The European healthcare technology and medical technology sectors have reached a definitive inflection point in 2026, transitioning from a period of venture-subsidised experimentation to an era of disciplined industrial maturity. This shift is characterized by a "Great Rationalization," where the market has moved past the speculative exuberance of the early 2020s and settled into a rigorous "flight to quality". Central to this transformation is the emergence of the "Founder B

The European HealthTech and MedTech M&A landscape in 2026 is poised for significant strategic acceleration, marking a transition from cautious, volume-driven dealmaking to high-value, transformative transactions. Deal flow is consolidating toward fewer but substantially larger deals, with market participants prioritising scalable technologies with robust clinical validation and AI integration capabilities.